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Abstract
Cerebral cavernous malformations (CCMs) are vascular lesions in
the central nervous system causing strokes and seizures which
currently can only be treated through neurosurgery. The disease
arises through changes in the regulatory networks of endothelial
cells that must be comprehensively understood to develop alterna-
tive, non-invasive pharmacological therapies. Here, we present the
results of several unbiased small-molecule suppression screens in
which we applied a total of 5,268 unique substances to CCM
mutant worm, zebrafish, mouse, or human endothelial cells. We
used a systems biology-based target prediction tool to integrate
the results with the whole-transcriptome profile of zebrafish CCM2
mutants, revealing signaling pathways relevant to the disease and
potential targets for small-molecule-based therapies. We found
indirubin-3-monoxime to alleviate the lesion burden in murine
preclinical models of CCM2 and CCM3 and suppress the loss-of-
CCM phenotypes in human endothelial cells. Our multi-organism-
based approach reveals new components of the CCM regulatory
network and foreshadows novel small-molecule-based therapeutic
applications for suppressing this devastating disease in patients.
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Introduction
Cerebral cavernous malformations are characterized by the presence
of vascular lesions that are most prevalent in the brain and can
occur sporadically or through a familial condition from mutations in
CCM1/KRIT1, CCM2/Malcavernin, or CCM3/PDCD10 [reviewed in
(Chan et al, 2010; Riant et al, 2010; Fischer et al, 2013)]. The loss
of CCM3 has particularly been associated with an early onset and
severe progression of the pathology (Riant et al, 2013; Shenkar
et al, 2015). Surgical resection is currently the only curative option
for CCM patients, but when lesions are seated deeply in regions of
the brain not accessible to neurosurgery, the condition may cause
severe morbidity or even lethality due to recurrent cerebral hemor-
rhages. Hence, pharmacological interventions are desperately
needed to (i) prevent the growth and bleeding of existing lesions
and (ii) to suppress the formation of new ones.
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Loss of CCM proteins in Caenorhabditis elegans, zebrafish, and
mouse leads to penetrant defects in vascular structures and
conserved signaling pathways. Importantly, these model organisms
offer many advantages for suppressing these phenotypes using
small molecules or genetic methods. In the nematode C. elegans,
complete loss of the CCM1 homologous gene kri-1 causes resistance
to apoptosis (Ito et al, 2010), whereas loss of ccm-3 causes defects
in biological tube development (Lant et al, 2015; Pal et al, 2017).
Similarly, loss of any of the Ccm proteins in zebrafish and mouse
causes cardiovascular malformations that result in cardiac defects,
including abnormal cardiac chamber ballooning, a failure of endo-
cardial cushions to form at the atrioventricular canal, and defects in
blood vessel formation (Mably et al, 2003, 2006; Hogan et al, 2008;
Boulday et al, 2009; Kleaveland et al, 2009; Zheng et al, 2010;
Yoruk et al, 2012; Renz et al, 2015; Zhou et al, 2015). In mice, the
endothelial-specific deletion of Ccm1-3 at postnatal day 1 leads to
lesions in the CNS and retinal vasculature which resemble CCM
lesions in patients (Boulday et al, 2011).
Several molecular pathways have been implicated mechanisti-
cally in the pathological changes that occur within endothelial
cells upon the loss of CCM proteins. These include signaling via
transcription factors KLF2/4 (Maddaluno et al, 2013; Renz et al,
2015; Zhou et al, 2015, 2016), the innate immunity TLR4 receptor
(Tang et al, 2017), MAPK (Uhlik et al, 2003; Fisher et al, 2015;
Zhou et al, 2015, 2016; Cuttano et al, 2016), b1-integrin (Bru¨tsch
et al, 2010; Faurobert et al, 2013; Renz et al, 2015), angiogenesis
and/or Notch (Boulday et al, 2009, 2011; Bru¨tsch et al, 2010;
Wu¨stehube et al, 2010; Zhu et al, 2010; You et al, 2013, 2017;
Renz et al, 2015; Schulz et al, 2015; Lopez-Ramirez et al, 2017),
Rho/ROCK (Glading et al, 2007; Whitehead et al, 2009; Borikova
et al, 2010; Stockton et al, 2010; Richardson et al, 2013), and
BMP/TGFb/endoMT or Wnt (Maddaluno et al, 2013; Bravi et al,
2015, 2016). In addition, the pathology may be accompanied by
increases in the production of ECM-degrading metalloproteases
(Zhou et al, 2015), the secretion of angiopoietin-2 (Jenny Zhou
et al, 2016), and oxidative stress (reviewed in Retta & Glading,
2016), or defective autophagy (Marchi et al, 2015) and apoptosis
(Ito et al, 2010). The identification of these misregulated signaling
pathways has suggested potential routes for pharmacological inter-
ventions, and molecules that modulate these pathways have been
tested in preclinical studies of murine endothelial-specific indu-
cible CCM models and even in clinical studies. These studies
investigated the potential of the Rho/Rock signaling inhibitors
fasudil or simvastatin (Zhou et al, 2015; Shenkar et al, 2017), the
blood pressure lowering drug propranolol (Reinhard et al, 2016),
the Wnt signaling inhibitor sulindac sulfone (Bravi et al, 2015),
the TGFb and pSMAD inhibitors LY-364947 and SB-431542 (Mad-
daluno et al, 2013), the TLR4 antagonist TAK-242 (resatorvid;
Tang et al, 2017), or treatment with antibiotics (Tang et al, 2017).
However, since many of these candidate drugs may cause severe
side effects in patients and because a comprehensive overview of
CCM-relevant molecular pathways is still lacking, the scientific
community has recognized the need of performing more system-
atic small-molecule screens. The fastest route to clinical trials for
drugs in the treatment of CCMs would be repurposed substances
already on the market. Recently, two screens based on Food and
Drug Administration (FDA)-approved small molecules have been
performed: the first, carried out on human CCM2-deficient
endothelial cells, led to the identification of several molecules
including tempol, a free radical scavenger, and vitamin D, neither
of which had previously been implicated in the treatment of this
disease (Gibson et al, 2015). Another screen assayed CCM3-defi-
cient mouse primary astrocytes and Drosophila glial cells for the
suppression of overproliferation. This led to the identification of
compounds affecting the mevalonate pathway (Nishimura et al,
2017). While these studies have provided important first insights
into potential therapeutic approaches, an unbiased, integrative,
and multi-organismic screen has not previously been attempted.
Performing such compound screens in the context of the complex
multi-tissue comprising CCM-deficient organisms may provide
comprehensive insights into conserved druggable pathways. Verte-
brate models with a cardiovascular system such as zebrafish offer
additional advantages that may not be available by screening
cultured cells or invertebrates. Hence, combined screens using
multiple systems are more likely to provide a comprehensive list
of CCM-relevant compounds.
Here, we present the results of a repurposed drug screen that
assayed the efficacy of suppressing cardiovascular defects in zebra-
fish ccm2m201 mutants or synthetic lethality in kri-1; ccm-3 double
mutants in C. elegans. Our study combines system biological analy-
ses integrating ccm2m201 mutant transcriptional data with molecular
pathways that have been modulated using small-molecule
compounds. These analyses pinpoint particular disease signatures
as critical hubs that could be targeted by therapies. In addition to
many previously identified compounds, our unbiased screen
provides a range of new candidates that affect angiogenesis, vitamin
D and retinoic acid signaling, blood pressure, ion channels, neuro-
transmitters, the oxidative stress/redox system, inflammation, and
the innate immune system. These findings provide an unbiased
framework for therapeutic approaches to tackle this debilitating
disease. The relevance of this unbiased screen for CCM therapeutics
is well illustrated by the identification of indirubin-3-monoxime as a
compound showing a rescue in human endothelial cells and a
strong preventive effect in CCM mouse models.
Results
Repurposed drug screens identify compounds that suppress CCM
mutant phenotypes in zebrafish and C. elegans
Most screens in the past have been primarily based on simplified
in vitro models that had only a limited ability to recreate the
complexity of the cardiovascular system or of the complex whole
organismal interactions that may be affected in the CCM pathol-
ogy (Gibson et al, 2015; Nishimura et al, 2017). To identify
compounds for a pharmacological suppression of CCM pheno-
types, we employed diverse assays on multiple organisms that
can help to discriminate distinct effects on the cardiovascular
system or cell biology upon loss of CCM proteins (Fig 1A). These
assays included screening small compound libraries at concentra-
tions of 10 lM for 24 h in zebrafish ccm2m201 mutant embryos
carrying the endothelial-specific reporter transgene Tg (kdrl:
GFP)s843 and probing for the suppression of the ballooning heart
phenotype at 48 h postfertilization (hpf) (Mably et al, 2006;
Materials and Methods). In parallel, we took advantage of the
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synthetic lethality caused by the co-ablation of kri-1 (CCM1) and
ccm-3 in C. elegans (Lant et al, 2015; Materials and Methods) and
screened for a restoration of viability, which led to insights into
cellular processes affected by the loss of CCM proteins that are
conserved between the species.
We screened a total of 1,600 unique compounds in zebrafish
(LOPAC/Selleck libraries), 8.4% of which (134/1,600) alleviated the
ccm2m201 mutant heart phenotype (Fig 1B–E; Dataset EV1). Concur-
rently, we screened 4,748 unique compounds [LOPAC/Selleck,
Spectrum, and GlaxoSmithKline protein kinase inhibitors (GSK-
PKIs)] in C. elegans kri-1(ok1251) mutants fed ccm-3 RNAi, 7.4% of
which (350/4748) rescued the synthetic lethal phenotype (Figs 1B
and EV1; Dataset EV1). The two screens identified six compounds
that had already been implicated in alleviating CCM loss-of-function
phenotypes in other models: sulindac sulfone (Bravi et al, 2015),
XMD8-92 (Cuttano et al, 2016), cholecalciferol (Gibson et al, 2015),
propranolol hydrochloride (Moschovi et al, 2010), simvastatin
(Whitehead et al, 2009), and sorafenib tosylate (Wu¨stehube et al,
2010; Table EV1).
Among the 1,080 compounds that were screened in both zebra-
fish and C. elegans, 32 suppressed CCM phenotypes in both models
(Fig 1B; Datasets EV1 and EV2). This overlap is highly significant
(P-value = 0) when compared to a random scenario. Finally, we
used human umbilical cord venous endothelial cells (HUVECs)
treated with CCM2 shRNA to screen 31 compounds that showed
rescue both in zebrafish and C. elegans and another 131 compounds
that had been particularly effective in one animal model or the
other. Of these 162 compounds, 26 rescued at least some features of
the CCM2 phenotype, which is characterized by an increase in the
formation of stress fibers, reduced levels of cortical ACTIN, and cell
shapes that are more elongated than control shRNA-treated HUVECs
(Faurobert et al, 2013; Materials and Methods; Fig 1B; Datasets EV1
and EV2). For example, indirubin-3-monoxime (IR3mo), which was
identified in the zebrafish screen, also gave a rescue in the HUVECs
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Figure 1. Small-molecule drug screens identify compounds relevant for CCM.
A Overview of the four different screening assays used in this study. Zebrafish embryos and C. elegans are screened in 24-well and 96-well plates, respectively. The
most promising active compounds are retested in shCCM2 HUVECs. One compound is tested for suppression of vascular lesion formation in the cerebellum of
iCCM2 and iCCM3 mouse models.
B Overlap of rescue compounds screened in the different assays.
C–E Examples of rescue of cardiovascular defects of the zebrafish ccm2m201 mutant. Inverted images of confocal z-scan projections of the 46 hpf head region and heart
(endocardium) of wild-type (WT) and ccm2m201 mutant zebrafish embryos carrying the endothelial Tg(kdrl:GFP)s843 reporter transgene. Embryos are untreated (C) or
treated between 17 and 48 hpf with 10 lM of the Lck inhibitor C8863 (D) or with 10 lM of the ERK5 inhibitor XMD8-92 (E). Both compounds resulted in a
reduction in heart size and narrowing of the heart tube at the atrioventricular canal (arrowheads). Scale bar is 100 lm.
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screen (Datasets EV1 and EV2). Five compounds showed some
degree of rescue in all three CCM models (Dataset EV2): the FLT3
angiogenesis inhibitor ENMD-2076, the PKC/phospholipase A2/D
inhibitor DL-erythro-dihydrosphingosine, the PI3K/Akt/mTor path-
way inhibitor ridaforolimus, the muscarinic acetylcholine receptor
antagonist DL-homatropine hydrobromide, and 13-cis-retinoic acid,
which has anti-inflammatory and anti-tumorigenic effects. Strik-
ingly, most of the molecular pathways targeted by these small mole-
cules had not previously been implicated in CCM.
Classification of compound activities
A functional annotation analysis based on the 18% (24/134) of the
zebrafish-active compounds and 20% (70/350) of the C. elegans-
active compounds with at least one Medical Subject Headings
(MeSH) term assignment revealed that they have a wide range of
therapeutic uses (Fig EV2), physiological effects (Fig EV3A), and
affect distinct molecular mechanisms (Fig EV3B). The comparison
of 102 different therapeutic, physiological, or molecular terms
according to which the compounds active in zebrafish and
C. elegans were classified revealed an enrichment of anti-inflamma-
tory, anti-hypertensive, neurotransmission modulatory, anti-oxida-
tive, or anti-neoplastic functions. Importantly, we found a number
of examples where different compounds with a shared pharmaco-
logical functional annotation alleviated CCM phenotypes only in
either one or the other animal model. These included vasodilatory
agents, for which felodipine (F 9677) affected only zebrafish and
carvedilol (C 3993) affected only C. elegans, or the sensory system
agents for which niflumic acid (N 0630) affected only zebrafish and
loxoprofen (L 0664) only C. elegans (Table EV2).
Target protein predictions reveal networks involved in CCM
Clustering analyses based on MeSH term assignments did not help
characterize the potential therapeutic, physiological, or molecular
activities of many compounds because their mode of action had not
yet been sufficiently defined to be assigned a MeSH term. To predict
additional protein targets of active compounds, we applied the
DePick computational target deconvolution tool. This draws on an
extended version of the human drug target prediction tool HitPick to
determine protein targets of small compounds identified in pheno-
typic screens (Liu et al, 2016; Materials and Methods). Based on
1,472 of 1,600 compounds with annotated targets in zebrafish and
4,170 of 4,748 in C. elegans, DePick predicted 47 and 134 human
proteins as statistically significant targets of the compounds identi-
fied in the zebrafish and in the C. elegans screens, respectively
(Table EV3; Dataset EV3). Several of the targets identified in the
C. elegans screen had previously been implicated in CCM; these
included TLR4 (Tang et al, 2017), metalloproteinases (MMP2,
MMP7, MMP13, MMP14; Zhou et al, 2015), and HMGCR (Nishimura
et al, 2017), which is a strong validation of the DePick method
(Table EV3).
DePick analyses revealed a number of important insights into the
regulatory network involved in CCM. First, DePick datasets identi-
fied a number of specific processes that were targeted in both zebra-
fish and C. elegans CCM mutants. We carried out comparative Gene
Ontology (GO) term analyses for biological processes (GO-BP) based
on the zebrafish and C. elegans DePick datasets (Ashburner et al,
2000; The Gene Ontology Consortium, 2017). We identified 42
significantly targeted GO-BP terms based on the zebrafish DePick
dataset; the analysis of the C. elegans dataset using these terms
revealed that 20 of those were also statistically significant (Dataset
EV4). Direct comparison of the zebrafish and C. elegans datasets
revealed that among the most significantly targeted proteins in both
compound screens were nine proteins with a role in vitamin D or
retinoic acid signaling (Table EV3; Datasets EV3 and EV4). In addi-
tion, GO-BP terms common to the two groups included cell cycle
control mechanisms (Dataset EV4). Biological processes exclusively
based on the zebrafish DePick dataset included signaling by the
PKB, PDGFR, and PI3K pathways (Dataset EV4).
Second, DePick datasets were used to visualize protein interac-
tion networks related to CCM based on the use of “Search Tool for
the Retrieval of Interacting Genes/Proteins” (STRING) clustering
algorithms for known protein interaction networks (https://string-
db.org/). These analyses revealed clusters among the proteins that
were present in both the zebrafish and C. elegans DePick target
datasets including vitamin D signaling proteins (CYP2R1 and
CYP24A1) and retinoic acid receptors (RAR and RXR; Figs 2 and 3,
and EV4). We also found that some of the most significantly
targeted proteins in the zebrafish dataset are clustered in the
VEGFR-dependent signaling pathway that controls angiogenesis
(KDR, FLT1, and FLT4; Fig 2). Additionally, we identified a protein
cluster comprising cytoskeletal and cell cycle-related proteins (tubu-
lins, polo-like kinase PLK1, and cyclin-dependent kinase CDK5),
which also was exclusive to zebrafish (Fig 2). In the C. elegans
DePick targets, we uncovered several protein clusters including one
related to lipid metabolism (ALOX5, ALOX12, ALOX15, ALOX15B,
and ALOX5AP; Fig EV4).
Third, DePick data helped analyze transcriptional changes
related to the loss of CCM proteins. We compared misregulated
genes from a previously published transcriptome of zebrafish
ccm2m201 mutant cardiac tissue (Renz et al, 2015) with the zebrafish
DePick target dataset (Howe et al, 2013) and found a significant
misregulation of nine of the 47 genes encoding proteins that were
directly orthologous to predicted target proteins. In line with the
protein interaction network data, these included the retinoic acid
receptor gene raraa, the cellular retinoic acid-binding protein genes
crabp1b and crabp2b, and the angiogenesis signaling receptors flt1,
kdr, and flt4 (Table EV4). To assess whether additional genes
related to disease-relevant genetic pathways might be affected, we
carried out comparative GO-BP term analyses based on the zebrafish
DePick dataset and found that only two GO-BP terms were also
significant for the zebrafish ccm2m201 mutant cardiac tissue dataset
(Ashburner et al, 2000; The Gene Ontology Consortium, 2017): In
line with evidence from several functional studies, our analyses
indicate that VEGF-dependent angiogenesis signaling is relevant to
the disease (Wu¨stehube et al, 2010; Zhu et al, 2010; You et al,
2013; Renz et al, 2015; Lopez-Ramirez et al, 2017), as well as reti-
noic acid signaling since several of these genes cluster under the
GO-BP term “anatomical structure morphogenesis” (Fig 2; Dataset
EV4). Furthermore, we found that the closely related GO-BP terms
“cytoskeletal organization” and “regulation of cytoskeletal organiza-
tion” were relevant for the zebrafish DePick and the zebrafish tran-
scriptome datasets, respectively (Table EV5; Dataset EV4). This
finding was in good agreement with the observation that CCM
mutant endothelial cells show defective cytoskeletal organization
4 of 17 EMBO Molecular Medicine 10: e9155 | 2018 ª 2018 The Authors
EMBO Molecular Medicine Pharmacological suppression of CCM Cécile Otten et al
Published online: September 4, 2018 
(Glading et al, 2007; Faurobert et al, 2013). In summary, compara-
tive analyses based on DePick target protein predictions have led to
the novel discovery of potential drugs that impinge on a set of
molecular pathways and biological processes that are affected in
both animal models, as well as a few that appear to be species-
specific.
Indirubin-3-monoxime shows rescue activity in different
CCM models
Given the stringent limitation inherent to mouse preclinical trials,
we defined a number of criteria as guidelines for compound selec-
tion: First, it should be a compound that is widely used in long-term
medical treatment plans but exhibits few or no side effects in
patients. Second, the compound should interfere with several
molecular pathways relevant to CCM. Finally, we ranked the posi-
tive effects of a drug in the zebrafish ccm model higher compared to
its effects in C. elegans due to the evolutionary conservation of the
vertebrate cardiovascular systems. Among the compounds identified
in the screen, we selected IR3mo, which suppressed the massive
cardiac ballooning phenotype of zebrafish ccm2m201 (Fig 4A–D) and
krit1ty219c mutants (Fig EV5A–D), for further tests in preclinical
mouse models even though it was not identified in the C. elegans
screen.
IR3mo is an FDA-approved drug with low toxicity derived from
traditional Chinese medicine that has been widely used to treat
leukemia and other chronic diseases (Eisenbrand et al, 2004;
Williams et al, 2011). Molecular studies demonstrated that indirubin
or its derivate IR3mo inhibits VEGFR2/KDR-dependent angiogenesis
(Zhang et al, 2011), among other targets and cyclin-dependent
kinases involved in cell cycle regulation (Hoessel et al, 1999). Based
on the zebrafish DePick dataset, three of 10 proteins predicted to be
targets of IR3mo were statistically significantly targeted in the screen
(SRC, VEGFR2/KDR, and MST1R), which suggested that IR3mo may
have its effects through its action on several targets (Fig 2;
Table EV6). So, even though IR3mo did not rescue the phenotype in
C. elegans, we considered it a good candidate for further studies.
We first addressed the issue of whether IR3mo could rescue
human endothelial cells and assayed its effects on siCCM1/KRIT1-
treated HUVECs, which are characterized by a massive formation of
stress fibers and elongated cell shapes (Fig 4E–H). In keeping with a
conserved effect in human endothelial cells, IR3mo treatment
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Figure 2. STRING network clustering for interactions of zebrafish DePick target proteins.
Nodes are DePick target proteins, with color coding according to Gene Ontology biological process (GO-BP) terms. GO-BP terms highlighted here are based on DePick target
protein predictions of compounds identified in the zebrafish screen. Asterisks indicate GO-BP terms which are also enriched in the zebrafish transcriptome of ccm2m201
mutant hearts (Renz et al, 2015). Edges are protein–protein associations. Line thickness represents the strength of data support.
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efficiently suppressed the cellular tension phenotype, restoring cells
to a rounded morphology with ruffled cell membranes (Faurobert
et al, 2013; Fig 4H). Similarly, CCM2- and CCM3-silenced HUVECs
were rescued by IR3mo treatment (Fig EV5E–J). Because CCM-
associated cardiovascular defects in mouse and zebrafish models
have been linked to an activation of the MEKK3-MEK5-ERK5 signal-
ing pathway (Zhou et al, 2015; Cuttano et al, 2016) and elevated
levels of KLF2 (Renz et al, 2015; Zhou et al, 2015, 2016), we next
tested the molecular effects of IR3mo treatment on these phenotypes
in different CCM models. Strikingly, IR3mo treatment efficiently
abolished the elevated levels of pERK5 in CCM1/KRIT1-depleted
HUVECs (Fig 4I–K). IR3mo treatment also reduced KLF2 mRNA to
wild-type levels in CCM1/KRIT1-depleted HUVECs, which is consis-
tent with a strong transcriptional activation of KLF2 by pERK5
(Fig 4L), and also reduced klf2a mRNA levels in ccm2m201 mutant
zebrafish embryos (Fig 4M). In summary, these results indicate that
IR3mo suppresses the hyper-activation of MAPK signaling and KLF2
induction upon loss of CCM proteins.
To elucidate the impact of IR3mo in a preclinical murine model
mimicking brain CCM lesions of the human brain vasculature, we
assayed its efficacy on the lesion burden in inducible endothelial-
specific knockout models of CCM2 and CCM3 (Boulday et al, 2009).
The induction of the conditional CCM2 or CCM3 knockouts at P1
resulted in a severe form of the disease that is characterized by
C. elegans DePick
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proteins of compounds identified in the C. elegans and zebrafish screens. See Fig EV4 for all DePick target protein names in this figure. Edges are protein–protein
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massive vascular lesions within the cerebellum by P8 (Fig 5A–D).
We found that feeding pups with IR3mo alleviated the burden of
lesions in both genetic conditions (Fig 5B and D). In particular, we
observed a significant reduction in the number of small lesions
(< 5,000 mm2) under this treatment plan in both genetic models
(Fig 5G and H). As a control, we found that treatment with IR3mo
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Figure 4. Indirubin-3-monoxime (IR3mo) rescues the CCM phenotype in zebrafish and HUVEC models.
A–D Treatment with 5 lM indirubin-3-monoxime (IR3mo) rescues the embryonic zebrafish ccm2m201 mutant ballooning heart phenotype. Shown are images of confocal
z-scan projections of wild-type (WT) (A, C) and ccm2m201 mutant (B, D) zebrafish embryonic hearts at 48 hpf expressing the endothelial reporter Tg(kdrl:GFP)s843
(cyan) and counter-stained for Alcam (magenta, labeling the myocardium). Scale bar is 50 lm.
E–H Treatment with 10 lM IR3mo for 48 h restores the wild-type ACTIN-adhesive phenotype in KRIT1-depleted HUVECs. Shown are confocal images of HUVECs with
labeled VE-cadherin (green) and F-ACTIN (red). Control siRNA-silenced (E, G) and KRIT1 siRNA-silenced (F, H) HUVECs were not treated (E, F) or treated (G, H) with
IR3mo. Scale bar is 10 lm.
I–K Treatment with IR3mo reduces phosphorylation of ERK (pERK) without affecting overall ERK protein levels. Shown in (I) are representative Western blots of KRIT1-
silenced HUVECs lysates treated or not with 10 lM of IR3mo during transfection. ERK5 (J) and phosphorylated ERK5 protein levels (K) were measured relative to
ACTIN protein levels based on three biological replicates with two technical replicates each (n = 3). Statistical analyses were performed using two-way ANOVA
followed by Tukey’s multiple comparisons test; error bars are SD. ****P < 0.0001; ns, not significant.
L Treatment with IR3mo rescues the elevated KLF2 levels of KRIT1-silenced HUVECs. RT-qPCRs were performed to measure KLF2 levels, on three biological replicates
(n = 3). Statistical analyses were performed using one-way ANOVA followed by Tukey’s multiple comparisons test; error bars are SD. ***P < 0.001; ns, not
significant.
M Treatment with IR3mo rescues the elevated klf2a levels of ccm2m201 mutant zebrafish embryos at 48 hpf. RT-qPCRs were performed to measure klf2a levels, on six
biological replicates (n = 6). Statistical analyses were performed using one-way ANOVA followed by Tukey’s multiple comparisons test; error bars are SD. *P < 0.05;
ns, not significant.
Source data are available online for this figure.
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had no effect on the width of the cerebellum (Fig 5E) and on the
animal weight (Fig 5F) of the iCCM2 mice at P8. These results indi-
cate that IR3mo efficiently suppresses CCM phenotypes in zebrafish,
mouse, and human endothelial cells.
Discussion
Here, we describe a repurposing drug screen applied to zebrafish
and C. elegans CCM models in which we uncovered 452
compounds that exhibited suppressive activity in at least one of
the organisms. A loss of CCM proteins affects the formation or
function of tube-like structures from the C. elegans excretory
canal to the zebrafish heart tube. Our approach to use pharmaco-
logical suppression to restore the tissue architecture that is
disturbed in CCM mutants involved organismal and cell-based
assays. This provided a highly integrated platform that exceeded
the complexity of previous purely cell-based high-throughput
screens (Gibson et al, 2015; Nishimura et al, 2017) and, hence,
provided a more comprehensive overview of relevant pathways
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Figure 5. Treatment of iCCM2 and iCCM3 mice with indirubin-3-monoxime (IR3mo) alleviates the lesion burden within the cerebellum.
A–D Shown are representative pictures of brains at P8 from iCCM2 (A, B) or iCCM3 (C, D) mice treated with vehicle (A, C) or with IR3mo (B, D). Mice were treated daily
between P2 and P7 with vehicle or with IR3mo. Scale bar is 1 mm.
E Treatment with IR3mo does not affect cerebellum width at P8 of iCCM2 mice. The measurements were performed on seven vehicle-treated and eight IR3mo-
treated mice (n = 7, n = 8). Student’s two-tailed t-tests were performed; error bars are SD. ns, not significant.
F Treatment with IR3mo does not affect animal weight at P8 of iCCM2 mice. The measurements were performed on eight vehicle-treated and eight IR3mo-treated
mice (n = 8, n = 8). Student’s two-tailed t-tests were performed; error bars are SD. ns, not significant.
G, H Quantifications of relative numbers of caverns within three categories based on cavern size. Cerebellar regions were measured in iCCM2 and iCCM3 mutants at P8
after treatment with vehicle (n = 8 for iCCM2 and n = 5 for iCCM3) or IR3mo (n = 8 for iCCM2 and n = 6 for iCCM3). Student’s two-tailed t-tests were performed;
error bars are SD. ns, not significant; *P < 0.05; **P < 0.01.
I Model scheme showing the molecular effect of IR3mo treatment on the ERK5 phosphorylation levels and the KLF2 expression levels in the CCM loss-of-function
context. Two arrowheads indicate different molecular effects of IR3mo within the ERK5-KLF2 pathway.
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affected in the disease. While these screens identified a number
of compounds that had not previously been implicated in CCM,
little overlap with other screens or known suppressing
compounds was reported. As a proof of the efficacy of our drug
screen, we identified many of the compounds or signaling path-
ways that had been discovered in previous screens or molecular
studies (Table EV1). We used the target prediction tool DePick
(Liu et al, 2016) to identify known targets including the innate
immunity receptor TLR4 (Tang et al, 2017), the metallopro-
teinases (MMP2, MMP7, MMP13, and MMP14; Zhou et al, 2015),
and HMGCR (Nishimura et al, 2017). In addition, we found a
number of compounds, both known and new, which affected
molecular processes or physiological functions that appear to be
relevant for CCM. These included anti-oxidants, analgesics,
neurotransmitter and ion channel modulators, protein kinase
inhibitors, and drugs with anti-hypertensive, anti-angiogenic,
anti-inflammatory/immunosuppressive, or anti-mitotic effects
(Figs EV2 and EV3). We were surprised to find that approxi-
mately 7–8% of all the compounds we tested had some effect on
the phenotype in zebrafish or C. elegans. This could be due to
the pleiotropy of molecular pathways that are relevant for CCM
and to the enrichment of bioactive molecules within the
compound libraries that were used. Our results strongly support
the initial hypothesis that such unbiased screens can identify
compounds with beneficial effects in the treatment or prevention
of CCMs. The inventory of relevant compounds also raises the
possibility of benefits to be gained through combinatorial treat-
ments based on drugs which target different molecular pathways
involved in the disease.
While whole-transcriptome analyses of CCM mutant animal
models have led to the identification of a number of misregulated
molecular pathways, clarifying their relevance to the disease has
remained a challenge (Renz et al, 2015). By employing small
molecules for probing relevant pathways and integrating transcrip-
tomics data with systems pharmacology analyses, we have now
identified a CCM-related signature that may point at critical hubs
including the VEGFR signaling pathway which will be important
for therapeutic applications. Unexpectedly, this analysis has
revealed a striking conservation of the effects of drugs on worms
and vertebrates, suggesting that some of these compounds may
also have beneficial effects in translational therapeutic applications
in the human disease. For instance, some of the compounds identi-
fied in both C. elegans and zebrafish were anti-hypertensive or
anti-angiogenic drugs. Of note, worms have no circulatory system,
and hence, these drugs may act by affecting more fundamental
functions of conserved molecular pathways—including roles that
go beyond those that have been well-established in vertebrate
physiology. Similarly, neurotransmitter-related agonists or antago-
nists had beneficial properties in both worm and zebrafish. This
class of drugs may function either autonomously on non-neural
tissues or non-cell autonomously on neural cells in their interac-
tion with the vasculature. Several compounds that affect MAPK
signaling exhibited suppressive effects on CCM mutant phenotypes
in worms and zebrafish. This finding suggests some cellular role
of MAPK signaling in both apoptosis in the worm and roles in the
vertebrate vasculature; until now, apoptosis was not among the
functional GO-BP terms for the ccm2 mutant transcriptome.
Finally, metabolites of the retinoic acid synthesis pathway and
drugs that affected the metabolic enzymes of this biochemical
synthesis pathway showed a potent capacity to suppress the CCM
phenotypes in zebrafish and C. elegans. Further studies are
required to assess the molecular role of this pathway upon the loss
of CCM proteins.
The effects of some small molecules may be due to targeting
multiple relevant pathways. An example is IR3mo, which is a
derivative of indirubin, the bioactive ingredient in a traditional
Chinese herbal medicine (Eisenbrand et al, 2004; Williams et al,
2011). Besides their anti-carcinogenic, anti-mitotic, and anti-
inflammatory effects, indirubin and its derivatives interfere with
angiogenic growth in the zebrafish embryo (Tran et al, 2007) and
in HUVECs. This may be due to an inhibition of VEGFR2 signal-
ing (Zhang et al, 2011). Other known targets of the drug include
CDKs (Hoessel et al, 1999; Davies et al, 2001) and GSK3b
(Leclerc et al, 2001). Indirubin compounds also affect signaling
by Notch 1 (Lee et al, 2008), b1 integrin (Kim et al, 2011), b-
catenin (Zahoor et al, 2014), and TGFb/BMP (Cheng et al, 2012),
and inhibit lipopolysaccharide-induced inflammation via TLR4,
which is mediated by the NF-jB and MAPK signaling pathways
(Lai et al, 2017). In mice, the lipopolysaccharide-induced stimula-
tion of TLR4 causes acute lung injury due to an increase in
oxidative stress and inflammation; indirubin treatment alleviates
this effect (Qi et al, 2017). Here, we found that IR3mo reversed
the molecular effects of activated MAPK signaling, which causes
the enhanced phosphorylation of ERK5 in siCCM1/KRIT1-treated
HUVECs and an increase in the transcriptional expression of
klf2a mRNA in zebrafish ccm2m201 mutants (Renz et al, 2015).
This shows that treatment with IR3mo not only reduces the
burden of lesions in murine preclinical models of CCM2 and
CCM3, but also has an impact on a key molecular pathway
involving MAPK signaling and endothelial KLF2 activation that is
functionally critical for ccm mutant cardiovascular defects in
zebrafish and mouse (Renz et al, 2015; Zhou et al, 2015, 2016;
Fig 5I). Although the precise mechanisms underlying disease
etiology in CCM mouse models are still unknown, probing the
effects of IR3mo will surely provide additional hints as to the
molecular mechanisms involved in the pathology. Interestingly,
DePick data have been an important tool not only for target
protein prediction but, equally important, for excluding less likely
target proteins. While GSK3b or CDK1/2 is well-characterized
targets of IR3mo, none of them is significantly targeted by other
compounds identified in the zebrafish screen (Table EV6). Hence,
systems biological approaches of identifying positive and ruling
out negative target proteins will further help to clarify CCM
pathology-relevant regulatory networks. Currently, we can only
speculate why IR3mo was not effective in C. elegans. For
instance, the worm cuticle may not be permeable for the
compound or IR3mo may target some of the pathways that are
specific for vertebrates.
In conclusion, this study reveals a number of novel compounds
affecting several molecular pathways and biological processes that
are conserved and relevant to both the basic cellular and more
complex cardiovascular defects found in CCM animal models rele-
vant to the CCM pathology in humans. In the future, systems biolog-
ical tools will help to improve our understanding of how these
molecular pathways are interconnected, which will greatly aid in
designing effective targeting therapeutics.
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Materials and Methods
Screen database
The compound collections [GlaxoSmithKline Published Kinase Inhi-
bitor Set (PKI, William Zuercher), The Library of Pharmacologically
Active Compounds (LOPAC, Sigma-Aldrich), Spectrum (Micro-
Source Discovery Systems, Inc), Selleck Library] were assembled
into a single structural data file, and unique identifiers were
assigned using Konstanz Information Miner software (KNIME;
Berthold et al, 2007). To check for structural overlap, we used the
KNIME CDK extension module for normalizing the compound struc-
tures (desalting step) and calculation of extended connectivity fin-
gerprints (ECFP-4; Beisken et al, 2013). Duplicate structures were
subsequently identified by Tanimoto similarity score calculation. All
screening results were integrated based on unique compound identi-
fiers. Screens were analyzed blindly.
Caenorhabditis elegans pharmacological suppression screen
Pharmacological suppression was adapted from liquid-based screen-
ing protocols (Lehner et al, 2006; Burns et al, 2015). Screens were
carried out in 96-well plates using synchronized L1-stage kri-1
(ok1251) mutant worms fed an E. coli HT115 bacterial strain express-
ing double-stranded RNA targeting ccm-3 (ccm-3 RNAi bacteria) from
the Source Bioscience LifeSciences feeding library. RNAi knock-down
was performed as previously described (Lehner et al, 2006) with
several modifications. The RNAi bacteria were grown to mid-log
phase and induced with isopropyl-b-D-thiogalactopyranoside (IPTG)
at a final concentration of 0.4 mM for 1 h at 37°C with shaking, then
pelleted, and concentrated 10-fold with liquid Nematode Growth
Media supplemented with 25 lg/ml carbenicillin and 2.4 mM IPTG
before dispensing into each well of the assay plates. The kri-1
(ok1251) strain (Ito et al, 2010) was obtained from the Caenorhabditis
Genetics Center. The E. coli HT115 strain carrying the L4440 empty
vector was used as a control for RNAi machinery induction, and pop-1
RNAi which produces a severe embryonic lethality phenotype was
used as a control for RNAi induction efficiency.
Library compounds were screened with a concentration of 60 lM
with a final concentration of DMSO of 0.6% v/v. Approximately 20
synchronized L1 larval stage kri-1(ok1251) worms were added to
each well of the 96-well plates in 10 ll of M9 buffer. Plates were
sealed with Parafilm and incubated for 13 days at 20°C with shaking
at 200 rpm. The screening was performed using a dissection micro-
scope by counting the number of living worms. The degree of phar-
macological suppression of the kri-1(ok1251); ccm-3 (RNAi) semi-
lethal phenotype was assessed based on a comparison of viability in
each compound to DMSO controls. The primary screen was carried
out in duplicate and candidate suppressor compounds were retested
at least once in triplicate using the same approach described above.
Representative pictures of the C. elegans screen as shown in Fig EV1
were recorded in brightfield on a Leica MZ FLIII microscope with
Leica 0.5× and 1.0× objectives and a Leica EC4 camera.
Zebrafish handling and maintenance
Handling of zebrafish was done in compliance with German and
Brandenburg state law and monitored by the local authority for
animal protection (LAVG, Brandenburg, Germany). The following
strains of zebrafish were maintained under standard conditions as
previously described (Westerfield et al, 1997): ccm2m201 and
krit1ty219c (Mably et al, 2006); Tg(kdrl:GFP)s843 (Jin et al, 2005); and
Tg(myl7:EGFP)twu34 (Huang et al, 2003).
Zebrafish pharmacological suppression screen
The zebrafish screen was performed by incubating approximately
15-20 embryos per well in 24-well plates. Screening plates were
prepared by automatically pipetting a 5 ll compound solution from
the LOPAC, Selleck, or Spectrum stock libraries (1 mM stocks, in
DMSO) into each well. Negative controls were wells without
compounds. At 17-19 hpf, dechorionated zebrafish embryos were
transferred within a volume of 0.5 ml E3 medium (5 mM NaCl,
0.17 mM KCl, 0.33 mM CaCl2, and 0.33 mM MgSO4) into each well
and incubated for 24 h at 28.5°C. For indirubin-3-monoxime treat-
ment (IR3mo, Sigma, #I0404), zebrafish embryos were incubated in
5 lM IR3mo/0.1% DMSO/E3 between 16 and 48 hpf. Control
embryos were treated with 0.1% DMSO/E3.
Live visual inspection was conducted under a fluorescence stere-
omicroscope. The cardiac phenotype of ccm2m201 mutants was
assessed for rescue with the wild-type siblings serving as internal
controls in each well. A pharmacological effect was considered a
rescue when ccm2m201 mutant hearts had a wild-type appearance or
had a less severe phenotype even when wild-type embryos were also
affected (e.g., the presence of blood flow, smaller heart, smaller
inflow tract size, and constricted atrioventricular canal). Candidate
suppressor compounds were re-screened. Representative pictures, as
shown in Fig 1 of heads of embryos fixed with 4% paraformaldehyde
(PFA) and embedded in 1% low-melting agarose, were recorded at a
LSM710 confocal microscope (Zeiss) with a 10× objective.
Zebrafish whole-mount immunohistochemistry
Zebrafish whole-mount immunohistochemistry, as shown in Figs 4
and EV5, was performed on 48 hpf embryos as previously described
(Renz et al, 2015). The following antibodies were used: mouse Zn-
8/Alcam (1:25, Developmental Studies Hybridoma Bank) and
DyLight 649-conjugated goat anti-mouse (1:200, Jackson ImmunoR-
esearch Laboratories, #115-495-003). Embryonic hearts were then
prepared and mounted in SlowFade Gold (Invitrogen, #S36936).
Images were recorded at a LSM 710 confocal microscope (Zeiss)
with a 40× objective.
Zebrafish RT-qPCR
Total RNA was extracted with TRIzol (Sigma) from pools of 7–15
embryos (48 hpf), and cDNA was synthesized with the RevertAid H
Minus First Strand cDNA Synthesis kit (Thermo Fisher Scientific).
Quantitative real-time PCRs (RT-qPCR) were performed as previously
described (Renz et al, 2015) in compliance with the MIQE standard
(Bustin et al, 2009) with six biological replicates, using 6 ng cDNA per
reaction. Measurements were performed on a PikoReal 96 Real-Time
PCR System (Thermo Fisher Scientific). Ct values were determined by
PikoReal software 2.2 (Thermo Fisher Scientific). Results were
analyzed using the comparative threshold cycle (Ct) method (2-DDCt)
to compare gene expression levels between samples as previously
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described (Renz et al, 2015). As an internal reference, we used zebra-
fish eif1b (Renz et al, 2015). The following primers were used:
Primer name Primer sequence
UniGene
identifier
Klf2aDr_fwd 50-CTGGGAGAACAGGTGGAAGGA-30 Dr.29173
Klf2aDr_rev 50-CCAGTATAAACTCCAGATCCAGG-30
Eif1bDr_fwd 50-CAGAACCTCCAGTCCTTTGATC-30 Dr.162048
Eif1bDr_rev 50-GCAGGCAAATTTCTTTTTGAAGGC-30
Since each single biological replicate represents an independent
experiment from an independent clutch of fish, one-way ANOVA
with Tukey’s multiple comparisons test was performed.
WT + DMSO: 1 (SD: 0); ccm2 + DMSO: 1.466 (SD: 0.22);
WT + IR3mo: 0.5778 (SD: 0.2458); ccm2 + IR3mo: 0.6992 (SD:
0.3278); n = 6 experiments.
Tukey’s multiple comparisons test Adjusted P-value
wt + DMSO versus ccm2 + DMSO 0.013 (*)
wt + DMSO versus wt + IR3mo 0.0305 (*)
wt + DMSO versus ccm2 + IR3mo 0.2296 (ns)
ccm2 + DMSO versus wt + IR3mo < 0.0001 (****)
ccm2 + DMSO versus ccm2 + IR3mo 0.0144 (*)
wt + IR3mo versus ccm2 + IR3mo 0.843 (ns)
HUVECs pharmacological suppression screen
Human umbilical vein endothelial cells (HUVECs) from pooled
donors (Lonza, #C2519A) were grown in EBM-2 basal medium
(Lonza, #CC-3156) enriched with EGM-2 (Lonza, #CC-4176) growth
factors at 37°C and 5% CO2 in a humidified cell chamber. They were
infected with pSICOR lentivirus expressing CCM2 shRNA 50
CACACTGTGGTGTTGTCATTG 30. This led to 70% reduction in
CCM2 expression, as verified by RT-qPCR.
shRNA ctrl shCCM2
ATP50 1 0.34184
Ranbp1 1 0.38087
RPLO 1 0.20438
mean 1.0 0.309
SEM 0.0 0.05352
Cells were then grown in a 384-well plate containing a different
10 lM compound solution in each well; negative controls were
wells containing 0.2% DMSO or no additive. Cells were then fixed
with 4% PFA and stained for the ACTIN cytoskeleton with Alexa
Fluor 647 Phalloidin to assess whether the cell elongation and stress
fiber phenotypes characteristic for CCM loss of function were
rescued. This experiment was performed in triplicate, as well as
repeated using compounds at 5 lM. Compounds were obtained
from the Sigma, Spectrum, and Selleck Libraries. The rescue efficacy
of the compounds was assessed blindly.
Indirubin-30-monoxime treatment of HUVECs
HUVECs from pooled donors (Lonza, #C2519A) were grown in
EBM-2 basal medium (Lonza, #CC-3156) enriched with EGM-2
(Lonza, #CC-4176) growth factors at 37°C and 5% CO2 in a
humidified cell chamber. Cells were transfected twice at a 24-h
interval with 30 nM KRIT1 siRNA oligonucleotides (Ambion,
#146529), CCM2 siRNA (Dharmacon #L-014728-01), siCCM3
(Dharmacon #L-004436-01), or CT siRNA (Dharmacon, #D-
001810-01) in Optimem (Gibco, #31985-047) using RNAi Max
lipofectamine (Invitrogen, #13778-150) as described in manufac-
turer’s instructions. HUVECs were treated with 10 lM IR3mo
(Sigma, #I0404) during the time of transfection. Untreated cells
were used as controls.
Immunohistochemistry of indirubin-30-monoxime-treated
HUVECs
HUVECs were grown and transfected as above, then seeded at con-
fluency (300,000 cells/well) on cover glasses in a 24-well plate
coated with fibronectin at 6 lg/cm2 (Faurobert et al, 2013). The
cells were treated with 10 lM IR3mo for 48 h prior to fixation with
4% PFA for 15 min at 37°C. Coverslips were blocked with 10%
goat serum and incubated with the primary antibody VE-Cadherin
mouse (Millipore, #MABT129) (1:200) for 1 h at 37°C and then
with the Goat anti-Mouse IgG Secondary Antibody Alexa Fluor 488
(Thermo Fisher Scientific, #A-11029) and TRITC-Phalloidin (Sigma,
#P-1951). Coverslips were then mounted in Mowiol. Immunofluo-
rescence pictures, as shown in Figs 4 and EV5, were acquired at an
Axioimager microscope (Zeiss) with an Orca R2 N/B camera
(Hamamatsu).
Western blotting of indirubin-30-monoxime-treated HUVECs
Cells were lysed in Laemmli buffer on ice. Lysates were soni-
cated and boiled, and proteins were separated by SDS–PAGE
using 10% acrylamide gel and transferred on a PVDF membrane.
Membranes were blocked 45 min at room temperature with a
5% BSA/TBST solution. The primary antibody was incubated
overnight at 4°C and HRP secondary antibody during 1 h at room
temperature. Signal was detected using ClarityTM Western ECL
Substrate (Bio-Rad) and Bio-Rad Chemidoc imaging system.
Western blots are representative of three experiments. Signals
were quantified using Image Lab (Bio-Rad). The following anti-
bodies were used for immunoblots: phospho-ERK5 (Cell Signal-
ing, #3371), ERK5 (Cell Signaling, #3372), ACTIN (Sigma, #A
3853), Peroxidase AffiniPure Goat Anti-Mouse IgG (Jackson
Immuno Research, #115-035-174), and Peroxidase AffiniPure
Fragment Donkey Anti-Rabbit IgG (Jackson Immuno Research,
#711-036-152).
ERK5 and pERK5 protein levels were measured relative to ACTIN
protein levels in a series of three biological replicates with two tech-
nical replicates each. Two-way ANOVA analysis was then
performed followed by Tukey’s multiple comparisons test.
Relative ERK levels: untreated control: 1 (SD: 0);
control + IR3mo: 1.06 (SD: 0.2463); untreated KRIT1: 1.15 (SD:
0.709); KRIT1 + IR3mo: 0.8926 (SD: 0.2403). Relative pERK levels:
untreated control: 1 (SD: 0); control + IR3mo: 0.1721 (SD: 0.0117);
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untreated KRIT1: 1.537 (SD: 0.4362); KRIT1 + IR3mo: 0.2709 (SD:
0.061).
Tukey’s test on
ERK5/ACTIN;
adjusted P-value
Tukey’s test on
pERK5/ACTIN;
adjusted P-value
ctrl versus ctrl + IR3 0.959 (ns) 0.0034 (**)
ctrl versus siKRIT1 0.6151 (ns) 0.0278 (*)
ctrl versus siKRIT1 + IR3 0.8117 (ns) 0.0083 (**)
ctrl + IR3 versus siKRIT1 0.8765 (ns) < 0.0001 (****)
ctrl + IR3 versus siKRIT1 + IR3 0.5337 (ns) 0.9436 (ns)
siKRIT1 versus siKRIT1 + IR3 0.1996 (ns) < 0.0001 (****)
RT-qPCR of indirubin-30-monoxime-treated HUVECs
Quantitative real-time PCR was performed in compliance with MIQE
guidelines (Bustin et al, 2009) with iTaqTM Universal SYBR Green
Supermix (Bio-Rad) on a C-1000 Touch Thermal Cycler (Bio-Rad) as
previously described (Renz et al, 2015). Ct values were determined
with the Bio-Rad CFX Manager. The following primers were used
for RT-qPCR:
Primer name Primer sequence
UniGene
identifier
For_KLF2 50-CATCTGAAGGCGCATCTG-30 Hs.744182
Rev_KLF2 50-CGTGTGCTTTCGGTAGTGG-30
For_ATP5O 50-ATTGAAGGTCGCTATGCCACAG-30 Hs.409140
Rev_ATP5O 50-AACAGAAGCAGCCACTTTGGG-30
For_RPLP0 50-TGCTCAACATCTCCCCCTTCTC-30 Hs.546285
Rev_RPLP0 50-ACTGGCAACATTGCGGACAC-30
For_RANBP2 50-TGTAGTGATACTGATGAAGACAATGG-30 Hs.199561
Rev_RANBP2 50-TTGTGCTAGTTATTTCTTCTGTCTGAG-30
Results were analyzed using the comparative threshold cycle (Ct)
method (2-DDCt) to compare gene expression levels between samples
as previously described (Livak & Schmittgen, 2001). The RT-qPCR
experiment was performed three times with three technical replicates
per experiment; KLF2 levels were normalized against three reference
genes RANBP2, ATP50, and RPLO. One-way ANOVA analysis was
then performed and followed by Tukey’s multiple comparisons test.
Untreated control: 1 (SD: 0); untreated KRIT1: 4.613 (SD: 1.044);
control + IR3mo: 0.4997 (SD: 0.1626); KRIT1 + IR3mo: 1.251 (SD:
0.5463).
Tukey’s multiple comparisons test Adjusted P-value
ctrl versus ctrl + IR3 0.7376 (ns)
ctrl versus siKRIT1 0.0003 (***)
ctrl versus siKRIT1 + IR3mo 0.9526 (ns)
ctrl+IR3 versus siKRIT1 0.0001 (***)
ctrl+IR3 versus siKRIT1 + IR3mo 0.4558 (ns)
siKRIT1 versus siKRIT1 + IR3mo 0.0006 (***)
Indirubin-30-monoxime treatment of iCCM2/3 mice
The iCCM2 (CCM2 flox/flox; Cdh5(PAC)-CreERT2) and iCCM3
(CCM3 flox/flox; Cdh5(PAC)-CreERT2) mouse lines were previously
reported (Boulday et al, 2011; Maddaluno et al, 2013) and main-
tained on a C57BL/6 background. Analyses of littermate pups were
performed at P7 or P8 (as indicated) without gender consideration.
Tamoxifen (Sigma) induction was performed as previously
described (Boulday et al, 2011) using a single intra-gastric injection
(20 lg/g). IR3mo (Sigma, cat# I0404) was administrated daily from
P2 to P7 at the oral dose of 10 mg/kg (diluted in 2% DMSO-
sunflower oil). Vehicle (diluent only) was administered following
the same protocol to obtain the control non-treated group. All exper-
imental animal procedures and mouse handling described in this
study were in full accordance with the European directive regarding
the protection of animals used for scientific purposes (Directive
2010/63/UE) and obtained authorization from the French Ministry
of Research after approval from the “Lariboisiere-Villemin” Ethic
Committee on animal testing (APAFIS#2769-201511061228356v3).
Animals were housed and bred in our local conventional animal
facility using standard individually ventilated cages, 12:12 light/
dark cycles, and ad libitum access to food and water.
For the iCCM2 experiment, eight IR3mo-treated and eight vehi-
cle-treated iCCM2 animals from three different litters were used. For
the iCCM3 experiment, six IR3mo-treated and five vehicle-treated
iCCM3 animals from two different litters were used.
We first assessed the weight of iCCM2 mice fed with vehicle
(4.4  0.24 g; n = 8) or with IR3mo (4.3  0.16 g; n = 8) and their
cerebellum width (vehicle: 6126.3  60.90 lm; n = 7; IR3mo:
6491.6  314 lm; n = 8). Student’s two-tailed t-tests showed that
there was no statistical significance between the two groups.
Assessment of lesion burden in iCCM2/3 mice
Lesion burden quantification was performed using digital imaging
resources (motorized Eclipse 80i, Nikon, combined to a high-sensi-
tivity cmos sensor camera) and a specialized image analysis software
(Nis Element AR, Nikon). Serial paraffin sections of half cerebellum
were prepared (10 lm thick), and hematoxylin and eosin (H&E) stain-
ing was performed on every 10 sections. Cerebral lesion burden
was quantified on each mosaic-reconstituted image of the entire
cerebellar section. Lesion were categorized depending of their area
(< 5,000 lm2; 5–10,000 lm2; and > 10,000 lm2). Results are
expressed as relative to the mean of total cerebellar area analyzed.
Student’s two-tailed t-tests were used to determine statistical signifi-
cance between two groups. The significance level was set at P < 0.05.
For iCCM2 (n = 8 for vehicle and IR3mo):
Size of lesions Tissue
Mean number
of lesions SD
t-test;
P-value
< 5,000 lm2 Vehicle 155.4 69.18 0.0338(*)
IR3mo 95.75 18.77
5–10,000 lm2 Vehicle 8.125 5.303 0.3457 (ns)
IR3mo 5.875 3.796
> 10,000 lm2 Vehicle 3.75 5.064 0.8970 (ns)
IR3mo 3.5 1.773
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For iCCM3 (n = 5 for vehicle and n = 6 for IR3mo):
Size of lesions Tissue
Mean number
of lesions SD
t-test;
P-value
< 5,000 lm2 Vehicle 197.7 26.34 0.0038 (**)
IR3mo 123.6 35.37
5–10,000 lm2 Vehicle 15.73 4.773 0.0403 (*)
IR3mo 7.305 6.525
> 10,000 lm2 Vehicle 7.548 3.561 0.5692 (ns)
IR3mo 5.775 5.837
Image and data analyses
Images were processed using common Fiji (Schindelin et al, 2012)
and Adobe Systems Bridge and Photoshop functions such as crop,
rotation, and white balance. Schemes were drawn, and figures were
assembled in Adobe Illustrator. Statistical data were analyzed using
Prism (GraphPad).
Medical subject headings (MeSH) categories of compounds
For MeSH category annotations of compounds, we used PubChem
CIDs corresponding to the InChI codes of compounds using the
pcp.get_compounds command of the publicly available python script
PubChemPy. We mapped to PubChem CIDs 1,497 and 4,306 of the
compounds tested in zebrafish and C. elegans, respectively. After-
ward, we queried rentrez (Winter, 2017), the Entrez R package from
NCBI, with those PubChem CIDs to obtain, when assigned, the asso-
ciated MeSH tree numbers in the category D (“Chemicals and
Drugs”) and subcategory D27 (“Chemical Actions and Uses”).
Finally, we classified the compounds into two subcategories of the
following three branches of the MeSH subcategory D27: “Molecular
Mechanisms of Pharmacological Action” [D27.505.519], “Physiological
Effects of Drugs” [D27.505.696], and “Therapeutic Uses” [D27.505.954].
DePick analysis of compounds
To determine pharmacological targets enriched in the set of
compounds active in zebrafish and C. elegans screens, we applied
an updated version of the published DePick target deconvolution
approach (Liu et al, 2016). Briefly, we obtained the known and
predicted targets (> 50% precision) of active as well as the inactive
compound sets of each organismal chemical screen using HitPickV2
(see detailed description below). After discarding highly promiscu-
ous compounds (with more than 100 known or predicted protein
targets), we applied the hypergeometric test (Benjamini–Hochberg
FDR correction < 10%) to search for pharmacological targets
enriched in the set of active compounds from the zebrafish and
C. elegans screens.
HitPickV2
HitPickV2 is an advanced version of the HitPick target prediction
method (Liu et al, 2013) that applies a novel ligand-based approach
to predict of up to 10 protein targets (among 2,736 human proteins)
per compound. For each query compound, HitPickV2 identifies the
closest, structurally similar compounds in the chemical-protein
interaction space (which consists of 891,629 annotated compound-
target associations) using k-nearest neighbors (k-NN; Nidhi et al,
2006) chemical similarity search and selects the space covering 10
distinct protein targets. Then, HitPickV2 scores and assigns a preci-
sion to these predicted targets based on the performance of
HitPickV2 in an in-house database assessed by cross-validation. The
precision depends on the number of target occurrence within the
restricted space of 10 targets, the ranking of the association of the
compound with those targets based on the scores of Laplacian-modi-
fied naive Bayesian models (Rogers & Hahn, 2010), and the Tani-
moto coefficient between the query and the most similar compound
with the annotated predicted target in such space.
Analysis of significant value for common shared active
compounds between zebrafish and C. elegans screens
We ran permutation analyses to assess the random expectation of
the number of active compounds shared by the C. elegans and
zebrafish chemical screens. For that, we randomly shuffled
1,000,000 times the activity values of all compounds (1,600, 1,080
of them were tested in C. elegans) tested in the zebrafish screen and
computed the number of active compounds also showing activity in
the C. elegans screen (total number of compounds screened 4,748).
Taking into account the distribution of the common active
compounds in the random sets and those with a shared number of
compounds equal or higher than 32 (actual number of shared
common hits), we derive a P-value. The P-value obtained was 0,
showing the statistical significance of the shared active compounds
between the two screens.
Gene ontology (GO) enrichment analysis of transcriptomics data
and DePick targets
GO biological processes (GO-BP) enrichment analyses of differen-
tially regulated genes of a zebrafish transcriptome experiment
(Renz et al, 2015) as well as DePick C. elegans and zebrafish
targets of chemical screens were performed using dedicated Perl
scripts. Associations connecting GO-BP terms and differentially
regulated genes (1,608) and background genes (10,652) in the
transcriptome experiment were extracted from the gene_associa-
tion.zfin goa_zebrafish.gpa files [downloaded from Gene Ontol-
ogy Consortium (Ashburner et al, 2000; The Gene Ontology
Consortium, 2017) on January 26, 2018)]. Associations between
GO-BP terms and zebrafish (47) and C. elegans (134) significant
human DePick targets as well as DePick background druggable
proteins (2719 with a GO-BP term) from chemical screens were
determined using the goa_human.gaf file (downloaded on
January 30, 2018 from the Gene Ontology Consortium). We then
propagated the GO-BP annotations to parent terms in the ontol-
ogy linked via the “is a” relationship. We applied the hypergeo-
metric test (Benjamini–Hochberg FDR correction < 10%) to
determine GO-BP terms enriched in the set of differentially regu-
lated genes in zebrafish transcriptome analysis (compared to the
background genes) and the DePick significant targets in zebrafish
as well as C. elegans chemical screens (compared to the drug-
gable target background).
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STRING
Analyses were done with STRING (Search Tool for the Retrieval of
Interacting Genes/Proteins) database version 10.5 (http://string-
db.org; Szklarczyk et al, 2015); Basic settings (using all active
interaction sources), minimum required interaction score: high
confidence. The Human DePick targets derived from the zebrafish
and from the C. elegans screens were analyzed against the DePick
background (2,695 druggable targets that could be mapped to
STRING identifiers). Network Statistics for zebrafish DePick:
number of nodes: 47; number of edges: 75; average node degree:
3.19; avg. local clustering coefficient: 0.633; expected number of
edges: 15; and PPI enrichment P-value: < 1.0e-16. Network Statis-
tics for C. elegans DePick: number of nodes: 134; number of edges:
266; average node degree: 3.97; avg. local clustering coefficient:
0.492; expected number of edges: 99; and PPI enrichment P-value:
< 1.0e-16. Edge Confidence: low (0.150); high (0.700); medium
(0.400); highest (0.900).
Expanded View for this article is available online.
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